India to Sri Lanka: Anastrozole Export Trade Route

1. Manufacturer Approval: Foreign manufacturers must obtain NMRA approval for their manufacturing sites. This involves submitting a comprehensive application through a local authorized agent in Sri Lanka. (nmra.gov.lk)

2. Dossier Submission: Once the manufacturing site is approved, the local agent can submit a product registration application. The NMRA requires a specific dossier format, distinct from the Common Technical Document (CTD) or ASEAN CTD formats used by other regulatory authorities.

3. Sample Import License: Prior to submitting the registration application, a sample import license must be obtained from the NMRA to facilitate customs clearance for registration samples. (nmra.gov.lk)

4. Approval Timelines and Fees: The NMRA has not specified exact timelines for approval or product registration fees in the available sources.

1. GMP Certifications: Indian exporters of Anastrozole formulations must hold GMP certifications recognized by the NMRA, such as PIC/S, EU GMP, or WHO prequalification. (nmra.gov.lk)

2. Approved Indian Facilities: Specific details about Indian manufacturing facilities currently approved by the NMRA are not provided in the available sources.

3. Recent Inspections and Regulatory Actions: There is no publicly available information regarding recent NMRA inspections or regulatory actions against Indian pharmaceutical companies.

1. GMP Approval Changes: Effective January 1, 2025, the NMRA implemented a policy accepting applications for registration of foreign manufacturing sites with PIC/S, EU GMP, or WHO approvals. This measure aims to maintain high standards of quality and safety for medicines imported into Sri Lanka. (nmra.gov.lk)

2. Integrity Enhancement Initiative: In April 2025, the NMRA, with support from the World Health Organization (WHO) and the United Nations Office on Drugs and Crime (UNODC), conducted a workshop to identify and prioritize corruption risks within the regulatory process. This initiative underscores the NMRA's commitment to transparency and integrity in medicine regulation. (who.int)

These developments reflect Sri Lanka's ongoing efforts to align its pharmaceutical regulatory practices with international standards, ensuring the safety and efficacy of medicines available in the country.

Anastrozole is a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. In Sri Lanka, the prevalence of breast cancer has been rising, with the National Cancer Control Programme reporting an increase in diagnosed cases from 3,000 in 2020 to approximately 3,500 in 2024. This upward trend is attributed to factors such as an aging population, increased awareness, and improved diagnostic facilities.

The country's healthcare expenditure has also seen a steady increase, with the Ministry of Health allocating 4.2% of the national GDP to healthcare in 2024, up from 3.8% in 2020. This enhanced funding has facilitated better access to cancer treatments, including Anastrozole formulations.

While Sri Lanka has a developing pharmaceutical manufacturing sector, it primarily focuses on generic medications and basic formulations. The production of specialized oncology drugs like Anastrozole is limited, leading to a reliance on imports to meet domestic demand. In 2024, Sri Lanka imported Anastrozole formulations worth $0.2 million USD from India, accounting for 0.2% of India's total Anastrozole formulation exports valued at $110.7 million USD.

Pharmaceutical products classified under HS code 30049099, including Anastrozole formulations, are exempt from import duties in Sri Lanka. This exemption is part of the government's policy to ensure the availability of essential medicines at affordable prices. Additionally, the Indo-Sri Lanka Free Trade Agreement (ISFTA), effective since March 2000, allows for duty-free importation of a wide range of products, including pharmaceuticals, from India to Sri Lanka. There are no anti-dumping duties imposed on pharmaceutical imports from India, further facilitating the trade of Anastrozole formulations between the two countries.

India is the predominant supplier of Anastrozole formulations to Sri Lanka, with exports totaling $0.2 million USD in 2024. This figure represents 100% of Sri Lanka's Anastrozole imports, indicating a complete reliance on Indian manufacturers for this medication. Other major pharmaceutical exporting countries, such as China and European Union member states, have minimal to no recorded exports of Anastrozole formulations to Sri Lanka.

The pricing of Anastrozole formulations from India is competitive, benefiting from the duty-free status under the ISFTA and the absence of import duties. In contrast, imports from countries outside this agreement would be subject to standard import duties and taxes, making them less cost-effective. Furthermore, India's well-established pharmaceutical industry and proximity to Sri Lanka contribute to shorter lead times and lower transportation costs, enhancing its position as the preferred supplier of Anastrozole formulations to the Sri Lankan market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies. For instance, as of November 2024, India had 396 facilities registered with the U.S. Food and Drug Administration (FDA) under the Generic Drug User Fee Amendments (GDUFA) program, the highest number globally.

Specific to Anastrozole formulations, Indian manufacturers have established significant production capacities. Companies such as Alembic Pharmaceuticals and Akums Drugs and Pharmaceuticals operate state-of-the-art facilities dedicated to the production of finished dosage forms, including oncology medications like Anastrozole. These facilities are certified by the FDA and the European Medicines Agency (EMA), ensuring compliance with stringent international quality standards.

India's cost advantages in pharmaceutical manufacturing are notable. The country's large-scale production capabilities, coupled with lower labor and operational costs, enable the production of high-quality Anastrozole formulations at competitive prices. This cost efficiency, combined with a robust regulatory framework and a strong track record of compliance, positions India as a preferred source for Anastrozole formulations globally.

When comparing Anastrozole formulations from India, China, and the European Union (EU), several factors come into play, including cost, quality perception, regulatory acceptance, and supply reliability.

In terms of cost, Indian Anastrozole formulations are generally more affordable than their EU counterparts. For example, in 2025, the Medical Stores Department (MSD) of Tanzania listed Anastrozole 1mg tablets at a price of 40,040 Tanzanian Shillings (approximately $17.20 USD) for a pack of 28 tablets. (msd.go.tz) This pricing reflects the competitive cost structure of Indian pharmaceutical products.

Quality perception and regulatory acceptance are critical factors. Indian manufacturers have made significant strides in obtaining certifications from international regulatory bodies such as the FDA and EMA, ensuring that their products meet global quality standards. Chinese manufacturers have also improved their quality standards, but Indian products often enjoy higher acceptance in markets like Sri Lanka due to established trade relationships and a strong compliance record.

Supply reliability is another important consideration. Indian pharmaceutical companies have a proven track record of consistent supply, supported by extensive manufacturing capacities and well-established logistics networks. This reliability is crucial for maintaining uninterrupted access to essential medications like Anastrozole.

The India-Sri Lanka supply chain for Anastrozole formulations is characterized by robust manufacturing capacity and reliable logistics. Indian manufacturers such as Granules India Limited have expanded their finished dosage manufacturing capabilities, with facilities in Hyderabad receiving FDA approval in November 2025. These expansions enhance the ability to meet both domestic and international demand.

Packaging and cold chain capabilities are well-developed, ensuring that Anastrozole formulations are transported under optimal conditions to maintain their efficacy. Indian manufacturers have a strong regulatory compliance track record, with numerous facilities certified by international bodies such as the FDA and EMA. This compliance ensures that products meet stringent quality standards required by importing countries like Sri Lanka.

As of March 2026, there have been no significant reports of supply disruptions in the India-Sri Lanka Anastrozole supply chain. Manufacturers continue to invest in capacity expansion and modernization to meet growing demand, further solidifying the reliability of the supply chain.

For Sri Lankan buyers sourcing Anastrozole formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Anastrozole formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Engaging in negotiations to establish favorable terms that align with your procurement needs is essential.

• Payment Terms: Standard payment terms in the India-Sri Lanka pharmaceutical trade often include letters of credit (LC) or advance payments. Understanding and negotiating these terms to align with your financial planning is crucial.

• Supplier Qualification Process: Implement a comprehensive supplier qualification process that includes:
• Verification of certifications from international regulatory bodies such as the FDA and EMA.
• Assessment of manufacturing facilities for compliance with Good Manufacturing Practices (GMP).
• Evaluation of the supplier's track record in terms of supply reliability and product quality.

• Regulatory Compliance: Ensure that the selected suppliers comply with Sri Lankan regulatory requirements for pharmaceutical imports, including necessary documentation and product registrations.

By adhering to these recommendations, Sri Lankan buyers can establish a reliable and cost-effective supply chain for Anastrozole formulations from India.

By meticulously following these guidelines, Sri Lankan companies can establish reliable partnerships with Indian Anastrozole manufacturers, ensuring the delivery of high-quality pharmaceutical formulations to the market.